Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP ‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP ‐1 RA use at screening

Feb 10, 2021Diabetes, obesity & metabolism

Switching to iGlarLixi versus continuing daily or weekly GLP-1 receptor drugs in people with type 2 diabetes not well controlled, analyzed by blood sugar levels and prior medication use

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Switching to iGlarLixi resulted in significantly greater reductions in HbA1c compared to continuing GLP-1 RA therapy at Week 26.

Participants switching to iGlarLixi had a higher proportion achieving HbA1c levels below 7% compared to those continuing GLP-1 RA treatment.
Significant reductions in fasting plasma glucose and 2-hour postprandial plasma glucose were observed with iGlarLixi, regardless of previous GLP-1 RA regimen.
Rates of hypoglycaemia were low but slightly elevated in the iGlarLixi group across all subgroups.
Modest weight gain was noted in individuals switched to iGlarLixi, independent of prior GLP-1 RA treatment.

AI simplified

AIM: In people with type 2 diabetes (T2D) requiring intensification beyond glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well-tolerated in the LixiLan-G trial. This exploratory analysis of LixiLan-G assessed the efficacy and safety of switching to iGlarLixi versus continuing GLP-1 RA therapy, stratified by screening HbA1c level (≥7.0 to ≤7.5 %; >7.5 to ≤8.0 %; >8.0 to ≤9.0 % [≥53 to ≤58 mmol/mol; >58 to ≤64 mmol/mol; >64 to ≤75 mmol/mol]) and previous GLP-1 RA regimen at screening (once/twice daily or once weekly).

MATERIALS AND METHODS: Endpoints for all subgroups included: change in HbA1c, achievement of HbA1c <7 % and hypoglycaemia events. Adverse events and changes in fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (PPG), 2-hour PPG excursion and weight were analysed according to previous GLP-1 RA regimen.

RESULTS: Switching to iGlarLixi in all subgroups resulted in significantly greater reductions in HbA1c and proportions of participants reaching HbA1c <7 % (including with no documented hypoglycaemia) at Week 26 compared with continued GLP-1 RA treatment. Switching to iGlarLixi also led to significantly greater reductions in FPG, 2-hour PPG, and 2-hour PPG excursion, irrespective of previous GLP-1 RA regimen. Rates of hypoglycaemia were low, but slightly higher in those who switched to iGlarLixi for all subgroups. Modest weight gain was seen with iGlarLixi, irrespective of previous GLP-1 RA regimen.

CONCLUSIONS: Switching to iGlarLixi improved glycaemic control, regardless of screening HbA1c or previous GLP-1 RA type, offering a simple, efficacious and well-tolerated treatment intensification option for people with T2D inadequately controlled by GLP-1 RAs and OADs.

Key numbers

0.6%

HbA1c Reduction

Mean reduction in HbA1c from screening to Week 26 for those switching to iGlarLixi.

53% to 69%

HbA1c Target Achievement

Proportion of participants achieving HbA1c <7% at Week 26 after switching to iGlarLixi.

+2.1 kg

Weight Change

Mean weight change from baseline to Week 26 for participants switching to iGlarLixi.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP ‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP ‐1 RA use at screening

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief